Senate Community Affairs Committee

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH AND AGEING PORTFOLIO

Supplementary Budget Estimates 2010-11, 20 October 2010

Question: E10-140

OUTCOME 14: Biosecurity and Emergency Response

Topic: PANDEMIC TIME LINE

Hansard Page: CA 22

Senator Fierravanti-Wells asked:

I request one document of key milestones in the whole [pandemic] process... including the various WHO announcements, the TGA's key milestones, the work of the technical advisory group on immunisation and the work of the US FDA.

Answer:

Key Dates for Pandemic Response and Vaccination Issues

Date	Activity
24 April 09	WHO announces detection of novel human influenza in Mexico
25 April 09	WHO declares the outbreak of swine influenza A/H1N1 a Public Health Emergency of
	International concern
27 April 09	WHO moves to pandemic phase 4 – sustained human to human transmission of a
	pandemic potential virus
28 April 09	Australia moves to pandemic phase DELAY – novel virus has emerged overseas but has not
	arrived in Australia
29 April 09	WHO moves to pandemic phase 5 – sustained community transmission in two or
20 4 11 00	more countries in one WHO region
30 April 09	National press advertising campaign - Public information on the national freecall H1N1
	09 hotline number (180 2007) and the health emergency website
	www.healthemergency.gov.au.
Mid - late	Discussions with CSL and Sanofi Pasteur regarding arrangements under the Deed. Discussions
May 09	with other vaccine manufacturers around availability and production timeframes for vaccine.
27 May 09	Television Commercials commence – to alert the public to cough and cold etiquette and
	advise the public on the sorts of symptoms associated with Swine Flu that people should
	be aware of.
28 May 09	Minister announced the Government would place an order for 21 million doses of vaccine from
	CSL.
29 May 09	Term Sheet signed by Health and CSL
1-6 June 09	Meetings with vaccine manufacturers around further supply of pandemic vaccine: Sanofi
	Pasteur, Novartis, Baxter, Protein Sciences, GSK.
3 June 09	Victoria moves to MODIFIED SUSTAIN – modified version of SUSTAIN which is realistic
	about extent of outbreak in community; mindful of disruption caused by some of public
	health measures and recognition of mild nature of illness in most people.
5 June 09	Effective date of the contract between CSL and Health
11 June 09	WHO moves to pandemic Phase 6 – start of new pandemic. Sustained community
	transmission in two or more WHO regions

17 June 09	Australia moves to pandemic phase PROTECT – recognition that pandemic virus is mild in
17 Julie 07	most but severe in some and moderate overall. Focus on treating and caring for those more
	vulnerable to severe outcomes.
22 Jul 09	First dose administered in CSL Australian <i>adult</i> clinical trial.
3 Aug 09	First dose administered in CSL Australian <i>children</i> clinical trial.
12 Aug 09	Second dose administered in CSL Australian <i>adult</i> clinical trial.
31 Aug 09	Pre-positioning of vaccine to CSL jurisdictional warehouses commenced.
3 Sep 09	First dose adult clinical trial report delivered by CSL.
10 Sep 09	
10 Sep 09	Preliminary results from the clinical trial of the vaccine in adults, published in the
	New England Journal of Medicine, provided clarification that only one dose was required for adults and children over 10.
15 Sep 09	FDA approved four pandemic (H1N1) 2009 vaccines manufactured by CSL Ltd,
	MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and sanofi pasteur Inc
	16 Nov 09 – FDA approved a fifth vaccine manufactured by <i>ID Biomedical Corp</i>
16 Sep 09	Purchase order signed for vaccine order (internal administrative process) and provided
10 Sep 09	to CSL
18 Sep 09	Therapeutic Goods Administration (TGA) approval to register vaccine for use in children 10 years and older and adults.
18 Sep 09	Minister announced the vaccination program would commence on
	30 September 2009.
18 Sep 09	The Prime Minister announced that Australia would commit up 10 per cent (21 million) of its
1	vaccine to the World Health Organization (WHO) for use in developing countries in our region.
18 Sep 09	ATAGI Statement
1	Guideline for the administration of pandemic (H1N1) influenza vaccine from multi-dose vials
	(MDV)
18 Sep 09	CMO advice to General Practitioners regarding the best use of MDV's for the vaccination
	program
24 Sep 09	Delivery of vaccine, consent forms, information sheets, VacPacs to vaccination providers
1	commenced.
24 Sep 09	ATAGI Statement
•	Use of multi-dose vials in vaccination programs
29 Sep 09	ATAGI Statement
	Advice regarding the use of influenza vaccines containing thiomersal (including pregnancy)
30 Sep 09	Pandemic (H1N1) 2009 Vaccination Program commencement.
30 Sep 09	Mass media communication campaign commences (radio, TV, newspaper) – Free pandemic
	(H1N1) 2009 vaccine available for adults and children 10 years and over to protect both the
	vulnerable groups and the general population against future waves of this virus.
Oct 09	The U.S. Government launched its national pandemic (H1N1) 2009 influenza vaccination
	campaign
8 Oct 09	ATAGI Statement
	Advice regarding influenza, influenza vaccines and Guillian-Barre Syndrome
9 Oct 09	ATAGI Statement
	Guidance on the use of latex-containing 1mL syringes from pandemic vaccination packs
12 Oct 09	CMO advice to General Practitioners regarding the latex in syringes leading to hypersensitivity
	reactions
Early Nov 09	FDA approved for use in the USA, CSL's Afluria (Influenza Virus Vaccine) for use in the
	paediatric population aged 6 months and older. This approval also included labelling for CSL
	Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine.
9 Nov 09	First dose children clinical trial report delivered by CSL.
19 Nov 09	ATAGI Statement
	Advice: on the use of seasonal vaccine as second dose in children
3 Dec 09	(TGA) approval to register vaccine for use in children aged 6 months to 9 years.
4 Dec 09	Vaccination of children aged 6 months to 9 years commences.
9 Dec 09	CSL commences distribution of Panvax Junior Pre filled syringes to immunisation providers
	(for use in children aged 6 months to 3 years).
17 Dec 09	ATAGI Statement
	Use of pandemic and seasonal influenza vaccines in children <10 years of age

22 Dec 09	ATAGI Statement Recommended clinical protocol for the administration of pandemic (H1N1) influenza vaccine
	from MDVs for children aged >6 months to <3 years and for all people aged >3 years
23 Dec 09	Second dose children clinical trial report delivered by CSL.
2010	
21 Mar 10	"Facts about Swine Flu" Campaign commences to help people understand the risks swine
	flu poses to the community, and the need for all people to get vaccinated.
10 Aug 10	WHO declares the move from phase 6 of the influenza pandemic alert to post
	pandemic period
26 Aug 10	The shelf life of Panvax® Junior pre-filled syringes reduced from 12 months to 6 months.
Oct 10	Australia donates a further 1.7 million doses of vaccine to the WHO, bringing Australia's
	total donation to 3.8 million doses.
1 Dec	Australia moves from PROTECT to ALERT phase
31 Dec 10	Vaccine Expires - Last date possible to receive Panvax H1N1 vaccine in Australia.